Parts of the plan have already been implemented, with additional reductions going into effect Octobe

Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million An

Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre

LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Compa

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday&#3

Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS)

Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company report

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Mond

Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-m

Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported recor

LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Compan

Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market s

Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical

LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Compan

Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session

Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing

Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.31 per share versus the Zacks C

Vivos Therapeutics (NASDAQ:VVOS) held its second-quarter earnings conference call on Friday. Below i

Vivos Therapeutics, Inc. (VVOS) Q2 2026 Earnings Call Transcript

Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.31) per share which beat the analy

LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan

Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in

Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday&#39

LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Compan

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#

Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

https://x.com/PatentGrants/status/2084730195765002647https://ppubs.uspto.gov/pubwebapp/external.html

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical

LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical

Vivos and Streeterville Extend Timeframe of Financing Agreement and Reaffirm Commitment to Convert D

Key Terms of the Proposed Rights OfferingExercise price: Each right is expected to entitle the holde

LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical

Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Inso

LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan

Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading me

Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Stre

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and r

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.52) per share which missed the ana

Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep C

Wall Street analysts changed their outlook on top names. For all rating changes, see analyst ratings